title: French Ministry of Health prospective multicentre study using bio-active stents coated with titanium nitride oxide: the EVIDENCE registry.
abstract: BACKGROUND
  Coronary stents have evolved over time, from bare-metal stents to drug-eluting stents, and now to bioactive stents.
  
  
  OBJECTIVE
  We sought to explore the immediate outcome of the titanium-nitride-oxide-coated bioactive stent, Titan2(®), in real-world practice, and the incidence of major cardiac events at follow-up.
  
  
  METHODS
  Consecutive patients admitted for percutaneous intervention for at least one significant (≥50%) lesion in a native coronary artery were treated with Titan2(®) stent implantation. The primary endpoint was total major adverse cardiac events at 12-month follow-up. Secondary endpoints included target lesion revascularization at 12-month follow-up and the duration of dual antiplatelet therapy.
  
  
  RESULTS
  Among 356 patients (mean age 67.4 ± 12.1 years), 77.2% were male and 39.3% were treated for myocardial infarction (MI). A total of 546 Titan2(®) stents were implanted in 420 lesions. Angiographic and clinical procedural success was achieved in all cases. No cases of in-hospital major adverse cardiac events or acute stent thrombosis were reported. Of 335 patients (94.1%) with 12-month clinical follow-up, four (1.2%) died, MI occurred in five (1.5%), target lesion revascularization was performed in 17 (5.1%) and major adverse cardiac events occurred in 24 (7.2%). One patient (0.3%) suffered late stent thrombosis during follow-up, but no cases of acute or subacute stent thrombosis occurred. Dual antiplatelet therapy continued beyond 6 months in 64.5% of patients.
  
  
  CONCLUSIONS
  In real-world practice, Titan2(®) stent implantation achieves an excellent immediate outcome, with a low incidence of major adverse cardiac events at 12-month follow-up.
authors.affiliation: Hôpital de Brabois, Vandoeuvre, France.
authors.forename: Michaël
authors.initials: M
authors.lastname: Angioi
authors.forename: Paul
authors.initials: P
authors.lastname: Barragan
authors.forename: Simon
authors.initials: S
authors.lastname: Cattan
authors.forename: Frédéric
authors.initials: F
authors.lastname: Collet
authors.forename: Patrick
authors.initials: P
authors.lastname: Dupouy
authors.forename: Philippe
authors.initials: P
authors.lastname: Durand
authors.forename: Jean
authors.initials: J
authors.lastname: Fajadet
authors.forename: Gérard
authors.initials: G
authors.lastname: Finet
authors.forename: Benoit
authors.initials: B
authors.lastname: Gerardin
authors.forename: Antoine
authors.initials: A
authors.lastname: Gommeaux
authors.forename: Bernard
authors.initials: B
authors.lastname: Karsenty
authors.forename: Christophe
authors.initials: C
authors.lastname: Loubeyre
authors.forename: Pierre
authors.initials: P
authors.lastname: Meyer
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Morice
authors.forename: Marc-Éric
authors.initials: MÉ
authors.lastname: Moulichon
authors.forename: Smain
authors.initials: S
authors.lastname: Sayah
authors.forename: Marc
authors.initials: M
authors.lastname: Silvestri
authors.forename: Xavier
authors.initials: X
authors.lastname: Tabone
authors.forename: Thierry
authors.initials: T
authors.lastname: Unterseeh
authors.forename: Olivier
authors.initials: O
authors.lastname: Wittenberg
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Lablanche
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000150:complications / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005602:France; D006077:Government Agencies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D012720:Severity of Illness Index; D015607:Stents; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D014025:Titanium; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible; D010975:Platelet Aggregation Inhibitors; C041500:titanium nitride; D014025:Titanium